Why Did Neovurse Divest?

On July 25th, Neovurse sold 2,770,781 convertible bonds in an off-market transaction, reducing its stake in Neofect from 13.67% to 8.25%. The official announcement stated this was a simple portfolio adjustment for investment purposes and there would be no change in management. However, given Neofect’s current financial difficulties, the market remains apprehensive.

Financial Challenges: Neofect’s Current Situation

Neofect is currently experiencing financial difficulties, marked by continuous operating losses. This is attributed to the slowing growth of its existing rehabilitation medical device business and the initial investment burden of its new automotive electronics software venture. However, the long-term growth potential of the rehabilitation medical device market and the potential of the new business are viewed as positive factors.

  • Key Financial Indicators (Dec 2022 – Dec 2024):
Indicator Dec 2022 Dec 2023 Dec 2024 Trend
Revenue 3,742 4,730 2,660 Increase then Decrease
Operating Income 298 672 -42 Increase then Sharp Decline
Net Income 221 503 24 Increase then Sharp Decline
Debt-to-Equity Ratio 53.02 41.50 32.07 Continuous Decrease
ROE 12.27 22.87 0.65 Increase then Sharp Decline
PER 8.17 6.71 89.70 Decrease then Sharp Increase

Investment Strategies: What Should Investors Do?

Neovurse’s divestment may negatively impact Neofect’s stock price in the short term. However, considering the long-term growth potential of Neofect, the current situation may present a buying opportunity at a lower price. Investors should carefully consider Neofect’s efforts to improve its financial health, the progress of its new business, and changes in the macroeconomic environment before making any investment decisions.